Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2022

Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study

Dates et versions

hal-03687586 , version 1 (03-06-2022)

Identifiants

Citer

C. Cottron, X. Treton, R. Altwegg, C. Reenaers, A. Amiot, et al.. Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study. 17th Congress of ECCO, Feb 2022, Vienna, Austria. pp.I502-I502, ⟨10.1093/ecco-jcc/jjab232.684⟩. ⟨hal-03687586⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More